Walt Disney, Bill Gates, and Shakespeare have more in common than anyone could imagine, united by the business imperatives embodied in the promise of blockchain technology.
This was just one of the things I learned after tuning into a recent SAP Game-Changers Radio broadcast entitled “Changing the Game in Life Sciences.” Host Bonnie D. Graham adroitly guided three experts through a fascinating exploration of blockchain’s potential to transform the life sciences industry with undreamed-of trust and efficiency for everything from drug discovery and tracking, to patient control of their own data.
Dream it, do it
Peter Ebert, senior vice president of business development and sales at Cryptowerk Corp., had every right to quote Walt Disney’s maxim, “If you can dream it, you can do it.” I saw proof of his company’s co-innovation during a VIDEO interview at SAP TechEd demonstrating a blockchain POC to help the pharmaceutical industry better track drugs. On the radio, Ebert was unsurprisingly optimistic, comparing Disney’s vision for Mickey Mouse in 1928 with blockchain’s potential to change people’s lives.
“Blockchain will not only be a technical technology or technical thing in our lives. It will impact all our experiences,” said Ebert. “If you go to the doctor and you’re getting blood drawn or you’re taking a pill…you want to make sure that this pill is not a counterfeit, that the technology around you and the devices are not counterfeit. Think about the doctor or other people treating you—you want to make sure that they have the education [and] the skills to treat you well and correctly.”
Ebert thought blockchain’s ability to prove authenticity to any digital asset had special significance to life sciences. “You can infuse this irrefutable trust into your supply chain of digital data assets,” said Ebert. “In life sciences, digital assets actually mean life or death. They’re not just any old assets; they are very precious data that relates to your life, to my life.”
Find blockchain architects for life science
While Deloitte reported 35 percent of surveyed health and life sciences organizations plan to deploy blockchain by 2018, Eric Piscini, principal, financial services practices, injected some caveats. His inspiration was a Bill Gates quote that stated, “We always overestimate the change that will occur in the next two years, and underestimate the change that will occur in the next 10. Don’t let yourself be lulled into inaction.”
“In the next two years we’ll talk about the blockchain, and 10 years from today we will not talk about blockchain anymore because blockchain will be embedded into everything that we do,” said Piscini.
The number-one challenge is finding people who understand both blockchain and life sciences.
“You need someone who understands what blockchain is capable of, the limitations, the challenges, and the opportunities from a technology point of view,” said Piscini. “You also need someone who can understand clinical trials, content management, and adverse effect management from a business point of view, and bring all of that together.”
Love all, trust a few
Joe Miles, global vice president of life sciences at SAP, turned to Shakespeare’s quote “Love all, but trust a few,” to describe how blockchain can deliver trust that helps patients and the medical industry.
“Blockchain is one of the many things that has a capability to really help simplify and automate trust,” he said. “To ensure that the appropriate people are seeing your information or your business information across all the different constituents that you deal with daily in a way that is productive and efficient.”
Miles thinks blockchain can streamline clinical trials, getting lifesaving products to market faster and more safely. “How do we reduce the time from compound to approval? How do we get this in the hands of the patients who need it to save lives all over? It’s expensive, it takes a lot of years,” he said. “Blockchain presents an opportunity to streamline that process to make it more transparent.”
Follow me on Twitter, SAP Business Trends, or Facebook. Read all of my Forbes articles here.